MORGAN STANLEY PLC/CALL/EDWARDS LIFESCIENCES/122.5/0.1/20.12.24 | Real-time Bid/Ask 12:29:34 14/06/2024 BST | ||
| 0.159 EUR / 0.192 EUR | +6.02% |
|
| Current month | +28.68% | ||
| 1 month | +93.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.16 | -3.61% |
| 13/06/24 | 0.166 | +1.22% |
| 12/06/24 | 0.164 | +2.50% |
| 11/06/24 | 0.16 | +21.21% |
| 10/06/24 | 0.132 | -8.33% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 10:01 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MG0KGG |
| ISIN | DE000MG0KGG0 |
| Date issued | 21/03/2024 |
| Strike | 122.5 $ |
| Maturity | 20/12/2024 (190 Days) |
| Parity | 10 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.29 € |
|---|---|
| Lowest since issue | 0.075 € |
| Spread | 0.033 € |
| Spread % | 17.28% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
87.67
USD
Average target price
96.24
USD
Spread / Average Target
+9.77%
- Stock Market
- Warrants
- Warrant